News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG (JOBS) Says its MS Therapy Reduces Relapses
September 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugmaker Novartis AG said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Novartis
MORE ON THIS TOPIC
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
January 2, 2026
·
1 min read
·
Annalee Armstrong
Phase III
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures
January 2, 2026
·
2 min read
·
Annalee Armstrong
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
December 23, 2025
·
2 min read
·
Nick Paul Taylor
Clinical research
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A
December 23, 2025
·
1 min read
·
Annalee Armstrong
